PTC Therapeutics | PTCT - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amgen USD 3.83B 130M 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Biogen USD 514.3M 128.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Cytokinetics USD -181.23M 2.86M 2026-03
Daiichi Sankyo JPY 89.54B 42.01B 2025-12
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Gilead Sciences USD 2.68B 284M 2026-03
Incyte USD 324.17M 59.7M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
Novartis USD 4.24B 171M 2026-03
Pfizer USD 4.99B 340M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Roche Holding CHF 9.56B 3.8B 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
TG Therapeutics USD 34.8M 15.7M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03
Xencor USD -77.86M 24.23M 2026-03